Myriad Genetics, Inc. Sustainability Profile
Myriad Genetics, Inc., a leading player in the precision medicine industry, is headquartered in the United States. Founded in 1991, the company has established itself as a pioneer in genetic testing and molecular diagnostics, focusing on areas such as oncology, women's health, and hereditary cancer. With a commitment to advancing healthcare through innovative solutions, Myriad offers a range of unique products and services, including genetic tests that provide critical insights for personalised treatment plans. The company has achieved significant milestones, including the development of the first FDA-approved genetic test for breast cancer risk assessment. Recognised for its contributions to the field, Myriad Genetics holds a strong market position, continually striving to enhance patient outcomes through cutting-edge technology and research.
DitchCarbon Score
How does Myriad Genetics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Myriad Genetics, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Myriad Genetics, Inc.'s reported carbon emissions
In 2022, Myriad Genetics, Inc. reported total greenhouse gas emissions of approximately 686,600 kg CO2e. This total comprises 404,000 kg CO2e from Scope 1 emissions and 282,600 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. Myriad Genetics has set ambitious near-term targets to significantly reduce its carbon footprint. The company commits to a 63% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2035, using 2024 as the base year. Additionally, it aims to reduce Scope 3 emissions from purchased goods and services, as well as fuel- and energy-related activities, by 66.33% per USD value added within the same timeframe. These targets align with the necessary reductions to limit global warming to 1.5°C, as classified by the Science Based Targets initiative (SBTi). The company's emissions data is not cascaded from any parent organisation, indicating that these figures and commitments are independently reported by Myriad Genetics, Inc.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Myriad Genetics, Inc.'s Industry?
How Carbon Intensive is Myriad Genetics, Inc.'s Location?
Myriad Genetics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Myriad Genetics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
